Lacosamide Zentiva (Lacosamide)

Lacosamide works by enhancing the slow inactivation of voltage‑gated sodium channels, which stabilizes neuronal membranes and reduces hyper‑excitability. It also binds to CRMP‑2, a protein involved in neuronal signaling, further contributing to its anticonvulsant effect.

The specific dose of Lacosamide Zentiva is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and other individual factors. Only a qualified healthcare professional should set the dosing regimen.

The safety of Lacosamide during pregnancy and lactation has not been fully established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a healthcare provider.

To order Lacosamide Zentiva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation and binding CRMP‑2—differs from many traditional antiepileptics that primarily affect fast sodium channels or GABA pathways. This can offer an alternative for patients who have inadequate response or intolerable side effects with other agents.

Lacosamide Zentiva should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct light to maintain its stability and potency.

Lacosamide Zentiva is taken orally, usually as a tablet, and should be swallowed with water. It is typically taken with or without food, following the dosing schedule prescribed by the treating physician.

Serious risks include the potential for suicidal thoughts or behavior, severe allergic reactions such as anaphylaxis, cardiac conduction abnormalities like atrioventricular block, and rare skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for any of these events.

Lacosamide should be avoided in patients with known hypersensitivity to the drug or its excipients, and in those with significant cardiac conduction disorders (e.g., PR‑interval prolongation) unless the benefits outweigh the risks. Clinicians should also exercise caution in patients with severe renal or hepatic impairment.